#ACR23 Abstr#1636 Phase 2 crossover RCT of Dazodalibep, Anti-CD40L-i in #Sjogren pts with high disease activity showed p

#ACR23 Abstr#1636 Phase 2 crossover RCT of Dazodalibep, Anti-CD40L-i in #Sjogren pts with high disease activity showed primary endpoint, change in ESSDAI was met in DAZ vs PBO. More COVID in DAZ in Stage 1 but trial was at the start of pandemic. Phase 3 is starting soon @RheumNow https://t.co/hZcpOHumB3